Newly-released In Situ Hybridization industry analysis report by Future Market Insights reveals that global sales of In Situ Hybridization in 2021 were held at USD 1.3 billion. With a 10.6% CAGR, the market is projected to reach a valuation of USD 3.9 billion by 2032.
Fluorescent In Situ Hybridization (FISH) is expected to be the highest revenue-generating technology, accounting for an absolute dollar opportunity of nearly USD 2.5 billion from 2022 to 2032.
| Attribute | Details |
|---|---|
| Global In Situ Hybridization Market (2022) | USD 1.4 billion |
| Global In Situ Hybridization Market (2032) | USD 3.9 billion |
| Global In Situ Hybridization Market CAGR (2022 to 2032) | 10.6% |
| The USA In Situ Hybridization Market CAGR (2022 to 2032) | 10.8% |
| Key Companies Profiled | Merck KGaA; Thermo Fisher Scientific; Agilent Technologies; PerkinElmer; Leica Biosystems Nussloch GmbH; BIO VIEW; NeoGenomics Laboratories, Inc.; Bio-Rad Laboratories, Inc.; Oxford Gene Technology; Advanced Cell Diagnostics, Inc. |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the In Situ Hybridization industry research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the In Situ Hybridization industry increased at around 9.9% CAGR, wherein, countries such as the USA, the Kingdom, China, South Korea, and Japan held a significant share in the global market. The market is projected to grow at a CAGR of 10.6% over the coming 10 years.
Some of the key factors driving the market include the rising prevalence of specific disorders, increased investments in in-vitro diagnostics, and technological advances in In Situ Hybridization (ISH).
Various research institutions and organizations have spent the last few years conducting extensive R&D in order to develop a technology that can evaluate the molecular profiles of single cells. For example, BIO-PROTOCOL created the Proximity Ligation in the In Situ Hybridization process. The method is expected to be high-performing, low-cost, quick multiplex, and simple to apply.
In situ hybridization technology has become more economical, making it more accessible to developing countries, which are more susceptible to infections and diseases. Regulatory organizations have implemented a variety of regulations and measures to raise public awareness. In August 2021, for example, the Federal Capital Public Health Agency in Nigeria cooperated with WHO to raise infectious illness awareness.
The utilization of ISH products has grown in recent years, resulting in an increase in the number of specialist contract research organizations. Reveal Biosciences, for example, uses in situ hybridization and other methodologies to deliver tissue research and innovative tissue technology services with strict legal capacity and high samples throughout.
For the past several years, cancer cases have been on the rise all around the world. Over the last few decades, extensive investigations on human diseases have identified recurrent genetic aberrations as potential driving factors for a range of malignancies.
Cytogenetic tests, such as ISH, aid in the combination of IHC and DNA FISH in situ, allowing researchers to create, discover and execute next-generation diagnostic approaches. Direct imaging of gene expression in situ at the RNA level gives a new perspective on the interaction between cancer cells and the tumor microenvironment as cancer progresses.
Furthermore, according to a study conducted by McMaster University in Canada, the number of people living with hemophilia has tripled to 1,125,000, up from 400,000 previously. Canada, France, Italy, Australia, the United Kingdom, and New Zealand are the countries most affected. The market is anticipated to benefit from this growth.
Principal Consultant
North America is expected to be the most lucrative region in the In Situ Hybridization Market throughout the analysis period. The market in the region is expected to be propelled by significant expenditure in healthcare Research and Development (R&D). The market in North America is projected to cross a valuation of USD 1.5 billion by 2032.
The USA dominated the In Situ Hybridization market in 2021, accounting for 44.9% of the total revenue. The existence of a large number of market players, as well as encouraging research programs by the regional government, can be credited for the regional market growth.
Other variables contributing to the country's dominance throughout the projection period include high healthcare spending and strict FDA and Health Canada rules. The USA In Situ Hybridization market has the most patents, whereas the Asia Pacific market has a greater marginal rise than the rest of the world. The presence of Health Canada-funded research initiatives and institutes is estimated to spur the market by a little margin.
The In Situ Hybridization market in the United Kingdom was valued at USD 72.5 million in 2021. The market in the country is expected to reach nearly USD 217.6 million by 2032. From 2022 to 2032, the market is likely to witness an absolute dollar opportunity of USD 147.1 million, growing at a CAGR of 11.9%
The In Situ Hybridization market in Japan is projected to reach a valuation of USD 183.8 million by 2032, growing at a CAGR of 10.1% from 2022 to 2032. The market is likely to garner an absolute dollar opportunity of USD 114.3 million from 2022 to 2032.
The market in South Korea is expected to reach a USD 75.1 million market value by 2032, growing at a CAGR of 8.5% from 2022 to 2032. During this period, the market is likely to gross an absolute dollar growth of USD 42.3 million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Fluorescent In Situ Hybridization (FISH) segment held the largest share of In Situ Hybridization market in 2021, accounting for around 54% of total revenue. This is due to the vast range of uses, including the diagnosis of congenital illnesses such as Edward's Syndrome and Down's Syndrome. The increased use of FISH technology as a result of the rising prevalence and treatment of such diseases is likely to accelerate In Situ Hybridization market growth.
The FISH market's growth is being fueled by low-cost technical advancements. For example, in May 2021, a group of researchers published a report claiming that using chromogen-based RNA in situ hybridization to identify druggable cytokines in atopic dermatitis and psoriasis is an efficient way. Technological progress broadens the scope of In Situ Hybridization and propels segment expansion.
The DNA probe segment held the largest share of in situ hybridization market in 2021, accounting for over 50% of total revenue. However, due to the development of novel nucleic acid-based diagnostic assays and instruments for studying DNA and RNA molecules, the demand for RNA probes grew at a faster rate in the anticipated timeframe.
By hybridization, an RNA probe can indicate the presence of similar nucleic acid sequences. The use of RNA as a hybridization technique is growing due to various advantages, including the fact that the probes are generated in vitro and may be used in practically all applications instead of DNA probes.
Revenue through application dominated the in situ hybridization market in 2021, accounting for over 35% of the total revenue. The expansion is expected to be fueled by an increase in the number of cancer cases. According to the American Cancer Society, about 1.9 million additional cancer cases are projected in the United States in 2021. With the surge in cancer cases, in situ hybridization methods for speedy and accurate diagnosis are in high demand.
Cancer is caused by a variety of reasons, including an aging population, poor health, and the environment. Various organizations are conducting cancer research and are encouraging advancements in cancer therapy. For example, the American Institute for Cancer Research funded around USD 110 million in cancer research grants from 2020 to 2021.
During the pinnacle of the epidemic, there was a significant drop in cancer and precancer diagnoses, owing to a decline in the number of screening tests done. In recent months, these characteristics may have hampered the utility of In Situ Hybridization as a molecular tool for cancer diagnosis. However, in the forthcoming years, the considerable development of FISH probes to visualize SARS-CoV-2 RNA in infected cells can have a favorable impact on the sector.
COVID-19 was also a motivating force behind the FISH market's expansion. The University of Oxford and the University of Warwick partnered in June 2021 to develop an in situ hybridization approach for detecting the COVID-19 virus in twenty minutes. This method has previously been used to detect diseases such as the Epstein-Barr virus and HIV inside cells. The In Situ Hybridization market growth is likely to accelerate in the near future because of these changes.
Some of the key players such as Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, PerkinElmer, and Leica Biosystems Nussloch GmbH.
Some of the recent developments of key In Situ Hybridization providers are as follows:
Similarly, recent developments related to companies offering In Situ Hybridization have been tracked by the team at Future Market Insights, which are available in the full report.
The global In Situ Hybridization market is worth more than USD 1.4 billion at present.
The value of In Situ Hybridization is projected to increase at a CAGR of around 10.6% from 2022 to 2032.
The value of In Situ Hybridization increased at a CAGR of around 9.9% from 2017 to 2021.
Top five players of In Situ Hybridization market include Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, PerkinElmer, and Leica Biosystems Nussloch GmbH
The top 5 countries driving demand for In Situ Hybridization are the USA, the United Kingdom., China, Japan, South Korea
1. Executive Summary | In Situ Hybridization Market 2. Market Overview 3. Market Risks and Trends Assessment 4. Market Background 5. Key Success Factors 6. Global Market Demand Analysis 2017 to 2021 and Forecast, 2022 to 2032 7. Global Market Value Analysis 2017 to 2021 and Forecast, 2022 to 2032 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Technology 8.1. Fluorescent (FISH) 8.2. Chromogenic (CISH) 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Probe Type 9.1. DNA 9.2. RNA 10. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 10.1. Services 10.2. Instruments 10.3. Kits & Probes 10.4. Software 11. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 11.1. Cancer 11.2. Cytogenics 11.3. Developmental Biology 11.4. Infectious Diseases 11.5. Other Applications 12. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. Asia Pacific 12.5. Middle East and Africa (MEA) 13. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 14. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032 15. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032 16. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032 17. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032 18. Key Countries Market Analysis 2017 to 2021 and Forecast 2022 to 2032 19. Market Structure Analysis 20. Competition Analysis 20.1. Merck KGaA 20.2. Thermo Fisher Scientific 20.3. Agilent Technologies 20.4. PerkinElmer 20.5. Leica Biosystems Nussloch GmbH 20.6. BIO VIEW 20.7. NeoGenomics Laboratories, Inc. 20.8. Bio-Rad Laboratories, Inc. 20.9. Oxford Gene Technology 20.10. Advanced Cell Diagnostics, Inc. 21. Assumptions and Acronyms Used 22. Research Methodology
Explore Healthcare Insights
View Reports
In Situ Hybridization Market
